TO THE EDITOR
Quantification of minimal residual disease (MRD) during and after antileukemic therapy is of growing interest in the treatment of acute myeloid leukemia (AML). Real-time reverse transcriptase polymerase chain reaction (PCR) is a widely used method for detection and quantification of MRD. Commonly used targets for MRD diagnostics in AML are fusion transcripts, including AML1-ETO, CBFB-MYH11 and PML-RARA. Recent studies have shown that it is possible to detect molecular relapse of AML before hematologic manifestation on the basis of increased ratios of fusion transcripts. In addition, it was possible to define threshold values at certain time points that predict relapses.
1 Quantitative RNA expression studies are usually carried out relative to the expression of a housekeeping gene as endogenous control to compensate for uneven cell numbers, RNA quality, or variations in reverse transcription efficiancies, of individual samples. The appropriate control gene for quantitative assessment should meet certain criteria. These include constitutive expression in all cell types at relative stable levels, stability and expression level comparable to the target gene. In addition, housekeeping genes with known existing pseudogenes should be neglected to avoid the amplification of genomic DNA. Housekeeping genes comprise a wide variety of genes that mainly code for proteins that are essential for the cell function.
2 Some of these genes code for components of the cytoskeleton (b-actin, a-tubulin), the major histocompatibility complex (B2M), enzymes of metabolic pathways (glycerolaldehydphosphate dehydrogenase (GAPDH), glucose-6-phosphate dehydrogenase (G6PDH), porphobilinogen deaminase (PBGD)) or enzymes of signaling pathways (ABL). Recently, some reports demonstrated that the expression of housekeeping genes varied considerably under experimental circumstances.
3 Therefore, the choice of an appropriate housekeeping gene as endogenous control is essential for the accuracy and reliability of a quantitative PCR approach. We quantitatvely analyzed the expression of AML1-ETO, CBFB-MYH11 and PML-RARA in AML samples relative to four different housekeeping genes -B2M, PBGD, G6PDH and ABL -by real-time reverse transcription (RT)-PCR using the LightCycler System. For all analyses, mRNA was automatically isolated by the MagnaPureLC (Roche, Mannheim, Germany), and cDNA was synthesized by random primed RT using Superscript II (Invitrogen Karlsruhe, Germany). Quantification of target and control genes was performed using standard curve analysis. The PCR protocols for AML1-ETO, CBFB-MYH11 and PML-RARA as well as G6PDH and ABL have been published, 1,4 while B2M and PBGD were quantified using the housekeeping gene kit B2M and PBGD, according to the manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). Bone marrow samples of AML patients were analyzed at diagnosis (n ¼ 29) and in follow-up samples (n ¼ 21) during and after cytostatic therapy. In addition, the expression of housekeeping genes was analyzed in the peripheral blood of healthy volunteers (n ¼ 14).
In the peripheral blood of healthy volunteers, the expression level was highest for B2M (mean crossing point (CP) 13.5, standard deviation (s. Table 1 .
A total of 29 samples of AML patients were analyzed at primary diagnosis. Seven samples were positive for AML1-ETO, seven for CBFB-MYH11, 15 for PML-RARA. Of the PML-RARA cases, nine revealed a bcr1 and six a bcr3 fusion type. The ratios of target gene to housekeeping gene expression of the corresponding samples were correlated to each other (ie (AML1-ETO/ABL)/(AML1-ETO/G6PDH)). The correlation coefficients (r) are demonstrated in Table 2 . In AML1-ETO-positive AML, all genes correlated well to each other. Only the ratio of AML1-ETO/G6PDH to AML1-ETO/B2M revealed a slightly weaker correlation. The expression level of ABL, G6PDH and PBGD were in the range of the AML1-ETO transcript as demonstrated by comparison of the mean CP. In contrast, B2M showed a higher expression level with a CP 7.5-8.7 PCR cycles earlier. The expression levels of CBFB-MYH11 showed significant correlation when quantified relative to the control genes ABL, G6PDH and B2M. PBGD revealed the weakest correlation to ABL and G6PDH. Again ABL, G6PDH and PBGD were expressed at levels in the range of CBFB-MYH11. In PML-RARA-positive AML, the ratios of ABL, G6PDH and B2M showed good correlation to each other. Quantification of PML-RARA relative to PBGD did not correlate to any of the other housekeeping genes. This was observed in the nine samples with bcr1 break point as well as in the six samples with bcr3 break point. As demonstrated in the other fusion genes, the expression levels of ABL, G6PDH and PBGD were in the range of PML-RARA, while B2M was expressed at clearly higher levels. In addition, quantitative analysis of AML1-ETO, CBFB-MYH11 and PML-RARA fusion transcripts was performed relative to the four housekeeping genes in 21 follow-up bone marrow samples of six AML patients -two t(8;21), two inv(16) and two t(15;17)-positive AML patients -during the course of antileukemic therapy. Again a ratio of target to housekeeping gene was formed and the ratios of the corresponding samples were correlated. In the follow-up samples during and after cytostatic therapy, relative quantification of MRD revealed highly significant correlation in all tested control genes (r ¼ 0.825-0.999).
In summary PBGD revealed the highest variation in the peripheral blood of healthy donors. Compared to the other genes, PBGD also revealed a slightly weaker correlation. At diagnosis of AML, PBGD correlated well to the other genes in AML1-ETOpositive AML. In CBFB-MYH11-positive AML correlation was weaker, while in PML-RARA-positive AML PBGD did not correlate to the other control genes at all. This was true for the bcr1 as well as the bcr3 subtype. These observations indicate that PBGD may be regulated in the leukemic blasts of PML-RARA-positive AML. In all follow-up samples, the variation of PBGD expression was not found. This is probably due to the fact that in follow-up samples, generally normal hematopoesis is the dominating population. Taken together, the use of PBGD as housekeeping gene for quantification of MRD in AML should not be recommended.
B2M exceeded the level of the other genes by far. The mean CP of B2M was 13.5 in the normal samples compared to 25.1 (G6PDH), 26.8 (PBGD) and 27.1 (ABL). Comparable results were also seen in the leukemic samples. A high expression of the control gene may increase the risk of false negative results especially if the target gene is expressed at low levels or if the quality of the sample is low. Therefore, B2M should be used with caution. In addition, there have been reports that B2M expression varies considerably in different lymphoid malignancies that may hamper the use of this housekeeping gene in such entities. 5 However, in our study, B2M revealed a stable expression in normal samples. The expression of B2M correlated well to ABL and G6PDH in all fusion gene groups at diagnosis as well as in the follow-up samples. Taken together, because of the risk of false negative results, the use of B2M as control gene is not recommended in AML.
G6PDH showed stable expression and correlated well to all other genes within the samples from healthy donors. The level of expression was in the range of ABL and PBGD and the tested fusion genes at diagnosis of AML. Within the follow-up samples, G6PDH again showed good correlation to the other genes in all fusion gene groups. At diagnosis of AML, G6PDH correlation was high to ABL and B2M in CBFB-MYH11-and PML-RARApositive AML. However, in AML1-ETO-positive AML, correlation of G6PDH was slightly weaker to B2M. Owing to the conflicting results in AML1-ETO-positive sample, G6PDH is not recommended as control gene of first choice for MRD studies in AML.
ABL was constantly expressed in the peripheral blood of healthy individuals at levels comparable to G6PDH and PBGD. Its expression level was also in the range of the fusion genes at diagnosis providing a high dynamic range of detection. Overall, ABL revealed the highest degree of correlation compared to the other control genes in normal donors and at diagnosis of AML1-ETO-and CBFB-MYH11-positive AML. Furthermore, good correlation was also found for B2M and G6PDH in PML-RARA-positive AML. Finally, quantification of MRD in follow-up samples using ABL also resulted in significant correlation to the other genes. Thus with highest priority, we recommend to use ABL for MRD studies in AML with t(8;21), inv(16) and t(15;17).
In chronic myelogenous leukemia (CML), Emig et al 4 recommended the use of ABL and G6PDH for quantification BCR-ABL transcripts. Another large study in CML confirmed that quantification of BCR-ABL transcript by real-time RT-PCR using ABL as control gene significantly correlates to cytogenetic techniques 6 Recently, a large multicenter EAC study on MRD quantification in leukemia has been published by Beillard et al 7 They focused on three control genes -ABL, B2M and GUS (bglucoronidase). Normal and various leukemic blood and bone marrow samples were analyzed. The three housekeeping genes were correlated between sample tissues, leukemia type and within the normal and the leukemic samples. ABL was the only housekeeping gene that did not differ significantly between tissues and leukemia type. In contrast to our analysis, the EAC studies were performed using a different detection system (ABI Prism 7700, Applied Biosystems). In addition, follow-up samples that generally demonstrate the majority and most interesting samples in MRD quantification were not examined. Our study confirms the results of the EAC trial recommending ABL as a control gene for MRD quantification in AML. Severe Congenital Neutropenia (SCN), also referred to as Kostmann's syndrome, is a rare inherited disorder characterized by a profound neutropenia linked to a maturation arrest of myeloid progenitors at the promyelocyte stage and an elevated prevalence (9%) of MDS/AML transformation. 1 A group of five acquired nonsense mutations (codons 716, 718, 720, 726 and 731) clustering in the median part of the intracellular domain of the G-CSF receptor (G-CSF-R) has been reported in SCN patients, mainly in those developing secondary MDS or AML.
2,3 All these mutations are C/T transitions introducing a STOP codon resulting in the deletion of the distal intracellular region of the G-CSF-R known to be involved in differentiation signaling. 4 Owing to the tight correlation noted between mutation occurrence and leukemic events in SCN patients, 2 the acquisition of these G-CSF-R mutations is suspected to be an important step in the leukemogenesis. Overall, 101 SCN patients have been enrolled in the French neutropenia registry, of whom six developed myelodysplasia/acute leukemia. During the course of G-CSF-R mutation screening in SCN patients of the French Neutropenia Registry, four patients were tested at the time they developed secondary malignant transformation. SCN was diagnosed according to previously described criteria (persistent profound neutropenia at a young age together with a maturation arrest of bone marrow myeloid progenitors).
1 Total RNA isolated from bone marrow mononuclear cells using the RNAplus reagent (Qbiogen, Illkirch, France) was reverse transcribed and submitted to PCR amplification between nucleotides 2310 and 2530, a fragment encompassing all the previously reported mutations, with forward primer 5 0 -GCTCA-GAGACCTGTGGCCTCCC-3 0 and reverse primer 5 0 -ATAG-GACTTGGGGCTGGGGGT-3 0 . PCR products were analyzed by (1) SSCP analysis performed at 201C in 12.5% polyacrylamide gels on a Genephor apparatus (Pharmacia Biotech), followed by a sensitive coloration with the DNA Silver Staining kit (Amersham Biosciences, Uppsala, Sweden), (2) restriction enzyme analysis with BfaI enzyme and (3) direct sequencing of purified PCR products. The nucleotide numbering is given according to the reference sequence whose accession number is gb:M59818.
Patient 1 (UPN 233015168), a girl with SCN diagnosed at 5 months old, was tested at 4 years of age when she developed an AML cytogenetically characterized by 46,XX,[2]/45, XX, . No G-CSF-R mutation was detected in this patient, both by SSCP, restriction analysis and direct sequencing of PCR products. The absence of mutation has been confirmed on DNA for this patient.
Patient 2 (UPN 233015200) had a SCN diagnosed at 2 months old. In this boy, G-CSF treatment was introduced at 4 months old and was continued until he developed a secondary MDS cytogenetically characterized by 45,XY,del(6)(q21),-7[15]/ 46,XY[5] at 9 years of age. The detected mutation, previously described in an SCN patient with secondary AML, 2 consisted of a C/T transition at nucleotide c.2396C4T, introducing a STOP codon at position 720 (Q720X).
Patient 3 (UPN 133015213) was a boy in whom SCN has been diagnosed at 2 months old. G-CSF treatment was initiated when he was 3 years old and continued until 8 years of age when he developed MDS/AML cytogenetically characterized by 47,XY,À7, þ 21, þ 21[9]/46,XY [5] . At this time, we detected a previously reported 5 C/T transition at nucleotide c.2390C4T introducing a STOP codon at position 718 (Q718X).
Patient 4 (UPN 233015129), a girl in whom SCN was diagnosed a few days after birth, was continuously treated by G-CSF from 5 years of age until 12 years of age, when she developed a secondary acute lymphoblastic leukemia (ALL) cytogenetically characterized by 48,XX,del(5)(q21q34), þ 21, þ 22(16)/46,XX [8] . ALL was diagnosed on the blast cells morphology (61% in peripheral blood, 75% in the bone marrow), MPO negativity and immunophenotyping, consistent with the diagnosis of a pre-B ALL: CD45 þ , CD19 þ , CD22 þ , CD33 þ , CD34 þ , CD38 þ HLA-DR þ and CD2À, CD3À, CD7À, CD10À, CD13À, CD15À, CD20À, CD41À and CD61À. No fusion gene (BCR-ABL, TEL-AML1, MLL-AF4, E2A-PBX) was identified by RT-PCR on diagnostic samples. In addition, as already reported on ALL blasts and lymphocytes, 6,7 G-CSF-R was detected on ALL blasts of our patient. The patient reached complete cytogenetic remission following induction therapy associating corticosteroids, vincristine and daunorubicin. Consolidation therapy associated courses of dexamethasone plus high-dose araC and courses of prednisolone, vincristine, methotrexate, cyclophosphamide and adriamycine. The patient remains in complete remission after cord blood allogeneic transplantation. To our knowledge, only one other case of ALL secondary to SCN has been reported so far. 8 Together with a slight phenotype difference (CD20 and CD22 positivity of the
